Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6356981 | 0.86 | PDE5A (0.38) | SMN1; SMN2PDE5A | |
| SCHEMBL3579719 | 0.85 | SMN1; SMN2 (0.38) | SMN1; SMN2PDE5A | |
| SCHEMBL6358740 | 0.84 | RAB9A (0.42) | — | |
| SCHEMBL6358537 | 0.82 | PDE5A (0.40) | SMN1; SMN2PDE5A | |
| SCHEMBL6807402 | 0.82 | PDE5A (0.36) | PDE5A | |
| SCHEMBL13500478 | 0.80 | ALDH1A1 (0.35) | SMN1; SMN2PDE5A | |
| SCHEMBL6806740 | 0.79 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL7100099 | 0.76 | RAB9A (0.36) | PDE5A | |
| SCHEMBL6200618 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2 | |
| SCHEMBL6442557 | 0.72 | SMN1; SMN2 (0.43) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | SMN1; SMN2 2159/4885PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.